Currently, replication-deficient adenovirus vectors and poxvirus vectors are widely used in vaccine R&D for a variety of infectious diseases in humans and animals, including AIDS, hepatitis B, ...

Please use one of the following formats to cite this article in your essay, paper or report: APA Sino Biological Inc.. (2025, March 12). Gilead’s capsid revolution meets our capsid solutions ...

As part of their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) can establish an infection in liver cells, researchers led by teams at Memorial Sloan ...

Get Instant Summarized Text (Gist) Research has identified a vulnerability in the hepatitis B virus (HBV) that could lead to new treatments. By disrupting the virus's ability to infect human liver ...

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate lenacapavir, a novel, once-yearly injectable HIV-1 capsid ... HIV-1/HBV co-infection ...

This is where the David Lab's expertise in how DNA gets packaged, read, and modified proved essential. They successfully generated the HBV minichromosome for the first time, using their ...

"During the more detailed characterization, we initially found that many of the antibodies were directed against the HEV capsid ... able to decipher the exact structure and mode of action ...

“During the more detailed characterisation, we initially found that many of the antibodies were directed against the HEV capsid ... able to decipher the exact structure and mode of action ...

Hepatitis B virus (HBV) infection remains an urgent global health concern, affecting hundreds of millions of people and significantly heightening the risk ...